Effects of azithromycin and rifampin on Chlamydia trachomatis infection in vitro

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 11, 2001, Pages 3001-3008

  Dreses Werringloer, U ^a   Padubrin, I ^a   Zeidler, H ^a   Kohler L ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BACTERIAL ANTIGEN; BACTERIUM LIPOPOLYSACCHARIDE; HEAT SHOCK PROTEIN 60; OUTER MEMBRANE PROTEIN; RIBOSOME RNA; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CELL CULTURE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LONG TERM CARE; PERSISTENT INFECTION; PRIORITY JOURNAL; RNA SYNTHESIS;

ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTITUBERCULAR; ANTIGENS, BACTERIAL; AZITHROMYCIN; CELL LINE; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; IMMUNOBLOTTING; MICROBIAL SENSITIVITY TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIFAMPIN; RNA, RIBOSOMAL; TUMOR CELLS, CULTURED;

EID: 0034769879     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.11.3001-3008.2001     Document Type: Article

References (59)

1. In vitro activity of azithromycin (CP-62, 993) against Chlamydia trachomatis and Chlamydia pneumoniae
2. Morphologic and antigenic characterization of interferon γ-mediated persistent Chlamydia trachomatis infection in vitro
3. Rifampicin - A new antitrachoma drug
4. Rapid determination of MICs of 15 antichlamydial agents by using an enzyme immunoassay (Chlamydiazyme)
5. Antibiotic susceptibility of Chlamydia trachomatis
6. Recurrent genitourinary, chlamydial infections in sexually active female adolescents
7. Chlamydia trachomatis: In vitro susceptibility of genital and ocular isolates to some quinolones, amoxillin and azithromycin
8. Prediction of efftcacy of antimicrobial agents in treatment of infectious due to Chlamydia trachomatis
9. Workshop on in vitro neutralization of Chlamydia trachomatis: Summary, of proceedings
10. Purification and partial characterization of the outer membrane protein of Chlamydia trachomatis
11. Antimicrobial drug susceptibility of 15 strains of Chlamydia trachomatis recently isolated from cases of nongonococcal urethritis in Italy
12. Enzyme-linked immunosorbent assay for "in vitro" detection of sensitivity of Chlamydia trachomatis to antimicrobial drugs
13. Low-nutrient induction of abnormal chlamydial development: A novel component of chlamydial pathogenesis
14. Protective efficacy of major outer membrane protein-specific immunoglobulin A (IgA) and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection
15. Evidence for long-term cervical persistence of Chlamydia trachomatis by omp1 genotyping
16. Persistence of Chlamydia trachomatis is induced by ciprofloxacin and ofloxacin in vitro
17. Genes required for assembly and function of the protein synthetic system in Chlamydia trachomatis are expressed early in elementary to reticulate body transformation
18. Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment
19. Lysis and biodegradation of microorganisms in infectious sites may involve cooperation between leukocyte, serum factors and bacterial wall autolysins: A working hypothesis
20. Single dose of azithromycin for the treatment of genital chlamydial infections in adolescents
21. Doxycycline and azithromycin for prevention of chlamydial persistence or recurrence one month after treatment in women. A use-effectiveness study in public health settings
22. The inflammatory cytokine response to Chlamydia trachomatis infection is endotoxin mediated
23. In vitro activity of rifamycins alone and in combination with other antibiotics against Chlamydia trachomatis
24. A randomized trial to compare 7 and 21 day tetracycline regimens in the prevention of recurrence of infection with Chlamydia trachomatis
25. Factors affecting chlamydial persistence or recurrence one and three months after treatment
26. Emergence of rifampin-resistance in Chlamydia trachomatis
27. Recurrence of urogenital Chlamydia trachomatis infection evaluated by mailed samples obtained at home: 24 Weeks' prospective follow up study
28. Ultrastructural and molecular analyses of the persistence of Chlamydia trachomatis (serovar K) in human monocytes
29. Ultrastructural analysis of the effects of penicillin and chlortetracycline on the development of a genital tract Chlamydia
30. In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection model
31. Cleavage of structural proteins during assembly of the head of bacteriophage T4
32. Single-dose oral azithromycin versus seven-day doxycycline in the treatment of non-gonococcal urethritis in males
33. In vitro activity of sparfloxacin and other antimicrobial agents against genital pathogens
34. A controlled trial of a single dose of azithromycin for the treatment of chlamydial urethritis and cervicitis
35. Electron microscopic observation on the effects of penicillin on the morphology of Chlamydia psittaci
36. Chlamydial disease pathogenesis. Ocular hypersensitivity elicited by a genus-specific 57-kD protein
37. Chlamydial disease pathogenesis. The 57-kD chlamydial hypersensitivity antigen is a stress response protein
38. Infrequent detection of Chlamydia trachomatis in a longitudinal study of women with treated cervical infection
39. Effect of IFN-γ on persistent infection by Chlamydia trachomatis serovar K in TPA-differentiated U937 cells
40. A double blind study of single dose azithromycin and doxycycline in the treatment of chlamydial urethritis in males
41. Minimum inhibitory and minimal lethal concentration against Chlamydia trachomatis dependent on the time of addition and the duration of the presence of antibiotics
42. Susceptibility of Chlamydia pneumoniae to azithromycin and doxycycline: Methodological aspects on the determination of minimal inhibitory and minimal bactericidal concentrations
43. Efficacy of single-dose azithromycin versus doxycycline in the treatment of cervical infections caused by Chlamydia trachomatis
44. Response of Chlamydia trachomatis serovar E to iron restriction in vitro and evidence for iron-regulated chlamydial proteins
45. The antimicrobial susceptibility of Chlamydia trachomatis in cell culture
46. In vitro activity of azithromycin against Chlamydia trachomatis
47. Inhibition of growth of Chlamydia trachomatis by human gamma interferon
48. In vitro activity of azithromycin, erythromycin, ciprofloxacin and norfloxacin against Neisseria ghonorrhoea, Haemophilus ducreyi and Chlamydia trachomatis
49. Azithromycin in the treatment of sexually transmitted disease
50. Chlamydia trachomatis-host cell interactions: Role of the chlamydial major outer membrane protein as an adhesin
51. In vitro studies of Chlamydia trachomatis susceptibility and resistance to rifampin and rifabutin
52. In vitro evaluation of C-62,933, erythromycin, clindamycin, and tetracycline against Chlamydia trachomatis
53. In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae
54. In vitro activity of azithromycin on Chlamydia trachomatis infected, polarized human endometrial epithelial cells
55. Persistent chlamydial envelope antigens in antibiotic-exposed infected cells trigger neutrophil chemotaxix
56. Repeat Chlamydia trachomatis infection in women: Analysis through a surveillance case registry in Washington State, 1993-1998
57. In vitro activity of 3-azinomethyl-rifamycin (SPA-S-565) against Chlamydia trachomatis
58. Protective monoclonal antibodies recognize epitopes located on the major outer membrane protein of Chlamydia trachomatis
59. The persistence of Chlamydia trachomatis elementary body cell walls in human polymorphonuclear leucocytes and induction of a chemiluminescent response